Table 4.
Serum immunoglobulin changes for patients who did not receive immunoglobulins during treatment
| IgA
|
IgM
|
IgG
|
||||
|---|---|---|---|---|---|---|
| Data for all four timepoints | All available data | Data for all four timepoints | All available data | Data for all four timepoints | All available data | |
|
Baseline
| ||||||
| Patients | 16 | 26 | 13 | 23 | 15 | 25 |
| Median (95% CI), mg/dL | 52·0 (32·0–115·0) | 46·0 (29·0–74·0) | 25·1 (9·0–45·0) | 25·0 (11·5–40·0) | 594 (440–685) | 625 (462–685) |
|
| ||||||
|
Cycle 3
| ||||||
| Patients | 16 | 22 | 13 | 18 | 15 | 21 |
| Median (95% CI), mg/dL | 74·0 (52·0–159·0) | 72·5 (53·0–144·0) | 25·8 (11·0–46·0) | 28·4 (13·0–44·0) | 541 (366–701) | 593 (403–701) |
|
| ||||||
|
Cycle 6
| ||||||
| Patients | 16 | 23 | 13 | 20 | 15 | 22 |
| Median (95% CI), mg/dL | 90·5 (70·0–155·0) | 94·0 (70·0–135·0) | 34·0 (21·0–50·0) | 34·5 (23·0–43·0) | 579 (450–734) | 623 (556–783) |
|
| ||||||
|
Cycle 12
| ||||||
| Patients | 16 | 19 | 13 | 16 | 15 | 18 |
| Median (95% CI), mg/dL | 101·0 (71·0–175·0) | 104·0 (75·0–175·0) | 37·0 (23·0–43·0) | 36·0 (23·0–43·0) | 596 (505–747) | 613 (517–747) |